Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2016

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2016
Published Nov 16, 2016
163 pages — Published Nov 16, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis Pipeline Review, H2 2016, provides an overview of the Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline landscape.

Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 7, 2, 7, 2, 13, 6 and 2 respectively.Ankylosing Spondylitis.

Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ankylosing Spondylitis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide

  
Source:
Document ID
GMDHC8639IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents28
  List of Tables81
  List of Figures91
Introduction101
  Global Markets Direct Report Coverage101
Ankylosing Spondylitis (Bekhterev's Disease) Overview111
Therapeutics Development121
  Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) Overview121
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics under Development by Companies132
Ankylosing Spondylitis (Bekhterev's Disease) Pipeline Products Glance154
  Late Stage Products151
  Clinical Stage Products161
  Early Stage Products171
  Unknown Stage Products181
Ankylosing Spondylitis (Bekhterev's Disease) Products under Development by Companies193
Ankylosing Spondylitis (Bekhterev's Disease) Companies Involved in Therapeutics Development2225
  AbbVie Inc221
  Alteogen Inc.231
  Amgen Inc.241
  BIOCAD251
  Biocon Limited261
  Bionovis SA271
  Brickell Biotech, Inc.281
  Celgene Corporation291
  Coherus BioSciences, Inc.301
  Genor BioPharma Co Ltd311
  Innovent Biologics, Inc.321
  Johnson &Johnson331
  Momenta Pharmaceuticals, Inc.341
  Mycenax Biotech Inc.351
  NeuClone Pty Ltd361
  Novartis AG371
  Oncobiologics, Inc.381
  Panacea Biotec Limited391
  Protalix BioTherapeutics, Inc.401
  Reliance Life Sciences Pvt. Ltd.411
  Sandoz International GmbH421
  Shanghai Pharmaceutical Co., Ltd.431
  Therapeutic Proteins International, LLC441
  Vitae Pharmaceuticals, Inc.451
  Xbrane Biopharma AB461
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Assessment479
  Assessment by Monotherapy Products471
  Assessment by Target482
  Assessment by Mechanism of Action502
  Assessment by Route of Administration522
  Assessment by Molecule Type542
Drug Profiles5690
  adalimumab biosimilar Drug Profile562
  adalimumab biosimilar Drug Profile581
  adalimumab biosimilar Drug Profile591
  adalimumab biosimilar Drug Profile601
  adalimumab biosimilar Drug Profile611
  adalimumab biosimilar Drug Profile621
  adalimumab biosimilar Drug Profile632
  adalimumab biosimilar Drug Profile652
  adalimumab biosimilar Drug Profile671
  adalimumab biosimilar Drug Profile681
  adalimumab biosimilar Drug Profile691
  adalimumab biosimilar Drug Profile701
  adalimumab biosimilar Drug Profile711
  adalimumab biosimilar Drug Profile721
  apremilast Drug Profile7311
  BBI-6000 Drug Profile842
  certolizumab pegol biosimilar Drug Profile861
  DNX-114 Drug Profile871
  DNX-514 Drug Profile881
  etanercept biosimilar Drug Profile891
  etanercept biosimilar Drug Profile902
  etanercept biosimilar Drug Profile921
  etanercept biosimilar Drug Profile931
  etanercept biosimilar Drug Profile941
  etanercept biosimilar Drug Profile951
  etanercept biosimilar Drug Profile963
  etanercept biosimilar Drug Profile991
  etanercept biosimilar Drug Profile1002
  golimumab Drug Profile1028
  golimumab biosimilar Drug Profile1101
  golimumab biosimilar Drug Profile1111
  infliximab biosimilar Drug Profile1121
  infliximab biosimilar Drug Profile1131
  infliximab biosimilar Drug Profile1143
  infliximab biosimilar Drug Profile1171
  infliximab biosimilar Drug Profile1183
  infliximab biosimilar Drug Profile1211
  infliximab biosimilar Drug Profile1221
  infliximab biosimilar Drug Profile1231
  INV-17 Drug Profile1241
  risankizumab Drug Profile1253
  secukinumab Drug Profile12813
  thalidomide Drug Profile1411
  upadacitinib tartrate Drug Profile1422
  VTP-43742 Drug Profile1442
Ankylosing Spondylitis (Bekhterev's Disease) Dormant Projects1462
Ankylosing Spondylitis (Bekhterev's Disease) Discontinued Products1481
Ankylosing Spondylitis (Bekhterev's Disease) Product Development Milestones14913
  Featured News &Press Releases1491
    Nov 03, 2016: Janssen to Present Data on SIMPONI ARIA (golimumab) at the 2016 American College of Rheumatology Meeting1491
    Oct 31, 2016: Novartis Wins Prestigious Prix Galien Foundation Award, Cosentyx as Best Biotechnology Product1501
    Sep 12, 2016: Innovent IBI303 to Initiate Pivotal Clinical Comparability studies with Adalimumab1511
    Aug 04, 2016: NICE draft guidance recommends new drug for people with ankylosing spondylitis1511
    Jul 17, 2016: SB5, An Adalimumab Biosimilar Referencing Humira, Accepted for Review by European Medicines Agency1521
    Jul 13, 2016: Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases1531
    Jun 28, 2016: Sandoz Canada Regulatory Submission for Subsequent Entry Biologic Etanercept Accepted for Review by Health Canada1531
    Jun 14, 2016: SIMPONI (golimumab) shows long-term treatment persistence and improved quality of life in patients with rheumatic diseases1541
    Jun 08, 2016: Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 20161551
    May 30, 2016: FLIXABI, Biogens Infliximab Biosimilar Referencing Remicade, Approved in the European Union1561
    May 23, 2016: Samsung Bioepis Biologics License Application for SB2 Infliximab Biosimilar Accepted by U.S. Food and Drug Administration1571
    Apr 27, 2016: COSENTYX - first Interleukin-17A inhibitor for psoriatic arthritis and ankylosing spondylitis approved by Health Canada1581
    Apr 01, 2016: FLIXABI, an Infliximab Biosimilar Candidate Referencing Remicade, Receives Positive CHMP Opinion1581
    Apr 01, 2016: Samsung Bioepis Flixabi Infliximab Biosimilar Recommended for Approval in the European Union1591
    Mar 16, 2016: Significantly higher persistence with SIMPONI (golimumab) in patients with rheumatic diseases compared with other subcutaneous TNF-alpha inhibitors, new study reveals1602
Appendix1622
  Methodology1621
  Coverage1621
  Secondary Research1621
  Primary Research1621
  Expert Panel Validation1621
  Contact Us1621
  Disclaimer1631

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2016" Nov 16, 2016. Alacra Store. May 03, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Ankylosing-Spondylitis-Bekhterev-s-Disease-Pipeline-Review-H2-2016-2088-16806>
  
APA:
Global Markets Direct - Market Research. (2016). Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2016 Nov 16, 2016. New York, NY: Alacra Store. Retrieved May 03, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Ankylosing-Spondylitis-Bekhterev-s-Disease-Pipeline-Review-H2-2016-2088-16806>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.